Abstract
To assess the compliance of treatment, its affecting factors, and reasons for dropout, a questionnaire was mailed to a cohort of 2139 subjects who received sildenafil prescriptions for erectile dysfunction (ED) at our institution from 1999 to 2002. A total of 726 subjects (34%) with a mean age of 67 years answered the questionnaires. The response rate for sildenafil treatment was 67%. Of these sildenafil responders, 43% reported that they continued using sildenafil while 57% did not, in a mean follow-up of 3 years. Common reasons for discontinuation were effect below expectations, high cost, loss of interest in sex, and inconvenience in obtaining sildenafil. The continuers showed a higher rate than the discontinuers (P<0.05) of having tried other treatments, dose titration, and a dose higher than 50 mg. The discontinuers reported having a lower mean responding dose and improvement score post sildenafil treatment than the continuers. In conclusion, effect below expectations was the leading reason for discontinuation of sildenafil treatment. How ED subjects tried the medication and the adequacy of education in the initial treatment period may impact the compliance of sildenafil treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wysowski DK, Swann J . Use of medications for erectile dysfunction in the United States, 1996 through 2001. J Urol 2003; 169: 1040–1042.
Jiann BP, Yu CC, Su CC . Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sale. Int J Impot Res 2004; 16: 527–530.
Jiann BP, Yu CC, Tsai JY, Wu TT, Lee YH, Huang JK . What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. Int J Impot Res 2003; 15: 412–417.
Hackett GI, Milledge A . A 12-month follow up of 260 patients taking sildenafil. NHS clinical experience. In: Fourth Congress of the European Society for Sexual and Impotence Research (ESSIR) 2001, 30 September–3 October 2001 (poster 171).
Casabe A, Cobreros C, Bechara A, Roletto L, Cheliz G, Hochman S et al. Drop out reason in responders to sildenafil. Int J Impot Res 2001; 13(Suppl 2): S5, (moderated poster 9).
Klotz T, Mathers M, Klotz R, Sommer F . Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra®)? Int J Impot Res 2005; 17: 2–4.
Son H, Park H, Kim SW, Paick JS . Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004; 6: 117–120.
Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC . Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541–1547.
Seftel AD . Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. J Urol 2003; 169: 1999–2007.
Harrold LR, Gurwitz JH, Field TS, Andrade SE, Fish LS, Jarry PD et al. The diffusion of a novel therapy into clinical practice: the case of sildenafil. Arch Intern Med 2000; 160: 3401–3405.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jiann, BP., Yu, CC., Su, CC. et al. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 18, 146–149 (2006). https://doi.org/10.1038/sj.ijir.3901379
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901379
Keywords
This article is cited by
-
Men’s beliefs about treatment for erectile dysfunction—what influences treatment use? A systematic review
International Journal of Impotence Research (2021)
-
Can low intensity shockwave therapy match the efficacy of phosphodiesterase-5 inhibitors for erectile dysfunction treatment? A pooled data analysis from two randomized clinical trials
International Journal of Impotence Research (2021)
-
Phenomenological and existential contributions to the study of erectile dysfunction
Medicine, Health Care and Philosophy (2021)
-
Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails
Drugs & Aging (2018)
-
Avanafil zur Therapie der erektilen Dysfunktion in der Praxis
MMW - Fortschritte der Medizin (2017)